Phaseline

Companies › Can-Fite BioPharma

Can-Fite BioPharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Namodenoson (CF102)
Adenosine A3 receptor agonist
ADORA3Phase 3Hepatocellular Carcinoma; Pancreatic AdenocarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05201404Namodenoson (CF102)Phase 3Hepatocellular CarcinomaOncologyFeb 2026
NCT06387342Namodenoson (CF102)Phase 2Pancreatic AdenocarcinomaOncologyDec 2026

From the company's SEC filings

Cash and short-term investments of $6m on 2025-12-31; operating cash outflow about $9m a year; runway about 7 months at that burn, to Aug 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Private offerings reported to the SEC (Form D)

Targets

ADORA3 (1)

Companies with the same targets

RDC Clinical

Companies built like this

LeonaBio RenovoRx Intensity Therapeutics Angiodynamics iTeos Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.